Higher-dose rifampicin for TB fluid around the heart
Treatments studied
Part of Heart & circulation, Infections clinical trials.
This Phase 2 study compares a higher dose versus the standard dose of rifampicin, a TB antibiotic, for people with TB-related fluid buildup around the heart. It aims to see which dose works better and is safe in improving TB pericarditis with fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have TB-related fluid around the heart confirmed on an ultrasound (echocardiogram)
- Start TB treatment (anti-TB therapy) within 5 days of beginning antibiotics
- Have TB confirmed from fluid around the heart or meet a “probable” TB definition based on symptoms and specific test results
- Be able and willing to have a procedure to drain the fluid from around the heart (pericardiocentesis), if your doctor recommends it
- Agree to TB testing that includes checking for HIV if your status isn’t already known
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This trial tests an intensified, shorter treatment plan for TB meningitis (TB in the lining around the brain) in adults, including people with HIV. It may help some patients get better with a structured plan while researchers compare treatment outcomes and safety.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This study tests whether giving a personalized dose of rifampin (a key TB medicine) can improve treatment. It is for people with active TB that is sensitive to rifampin, and it involves frequent blood and urine tests to measure drug levels.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
This trial tests whether a shorter, rifampicin-based treatment works well for people with less severe TB in the lungs. If you have limited TB that is sensitive to rifampicin, you might be able to take medicine for a shorter time than usual.
Hear when a new Tuberculous Pericarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.